S. 3064 · Where this bill is now
In committee
Introduced in the Senate, Oct 28, 2025
What this bill does
In plain words · AI-written from the official summaryMedicare cuts costs for chronic pain drugs
This bill makes it easier and cheaper for people on Medicare to get non-opioid drugs that treat chronic pain. It removes the upfront deductible you'd normally pay for these drugs, puts them in the lowest cost tier, and stops insurance plans from requiring you to try other drugs first or get prior approval before using them.
How it affects you
If you're on Medicare and manage chronic pain with non-opioid medications, you'd pay less out of pocket and face fewer delays getting the drugs your doctor prescribes. The bill doesn't affect people on other types of insurance or those who use opioid pain medications.
Read the official summary (Introduced in Senate, Oct 28, 2025)
Relief of Chronic Pain Act of 2025
This bill reduces cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid drugs for chronic pain management.
Specifically, the bill requires such drugs to be covered without a deductible and to be placed on the lowest cost-sharing tier (if any). The bill also prohibits the imposition of prior authorization requirements (i.e., requiring prior approval from a plan) or step therapy requirements (i.e., requiring the use of alternative drugs before a drug is covered under a plan) with respect to such drugs.
Written by AI (Claude) using only the official summary by the Congressional Research Service, the Library of Congress’s nonpartisan research staff. It can miss nuance, so check the official summary and the bill text for details.
1st SessionS. 3064
A BILL
Relief of Chronic Pain Act of 2025
Sponsor: Sen. Steve Daines (R-MT) · Introduced Oct 28, 2025 · Health · 1 version of the text
Sources: Congress.gov actions and votes · bill text from GovInfo · latest official action Oct 28, 2025: “Read twice and referred to the Committee on Finance.”